ETC
CPRX

Exchange Traded Concepts’s Catalyst Pharmaceutical CPRX Stock Holding History

Exchange Traded Concepts’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.04M Buy
65,056
+2,503
+4% +$73.9K 0.01% 713
2026
Q1 		$1.55M Sell
62,553
-7,234
-10% -$172K 0.01% 668
2025
Q4 		$1.63M Buy
69,787
+6,816
+11% +$152K 0.01% 639
2025
Q3 		$1.24M Buy
62,971
+61,250
+3,559% +$1.26M 0.01% 702
2025
Q2 		$37.3K Buy
1,721
+132
+8% +$3.12K ﹤0.01% 1342
2025
Q1 		$38.5K Sell
1,589
-550
-26% -$12.4K ﹤0.01% 1235
2024
Q4 		$44.6K Buy
2,139
+132
+7% +$2.84K ﹤0.01% 1233
2024
Q3 		$39.9K Sell
2,007
-21,072
-91% -$391K ﹤0.01% 1218
2024
Q2 		$357K Buy
23,079
+21,963
+1,968% +$342K 0.01% 747
2024
Q1 		$17.8K Sell
1,116
-160
-13% -$2.41K ﹤0.01% 1078
2023
Q4 		$21.4K Sell
1,276
-29,960
-96% -$410K ﹤0.01% 1042
2023
Q3 		$365K Buy
+31,236
New +$418K 0.01% 716

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Exchange Traded Concepts's CPRX Position: Q2 2026 in Review

Exchange Traded Concepts increased its Catalyst Pharmaceutical (CPRX) stake by 4% in Q2 2026, buying an estimated $73.9K and bringing the position to 65,056 shares worth $2.04M. The position accounts for 0.01% of the portfolio, ranked #713.

Exchange Traded Concepts first reported a position in CPRX in Q3 2023 and has held it in 12 quarters since. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Exchange Traded Concepts held 65,056 shares of Catalyst Pharmaceutical worth $2.04M as of Q2 2026.
  • Exchange Traded Concepts bought 2,503 Catalyst Pharmaceutical shares in Q2 2026, an estimated $73.9K.
  • Catalyst Pharmaceutical made up 0.01% of Exchange Traded Concepts's portfolio in Q2 2026, its #713 holding.
  • Exchange Traded Concepts first reported a position in Catalyst Pharmaceutical in Q3 2023 and has held it in 12 quarters since.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Exchange Traded Concepts's 13F filing for Q2 2026, filed 22 Jul 2026.